Thank you, Madam Chairperson.
I think we're going to have to carry on with Mr. Benoit. There are so many questions with respect to PMPRB and the amount of money as part of the supplementary estimates.
I have a couple of questions. The first has to do with the fact that you say you don't use manufacturing costs to determine the price of new drugs because prices are not related to the manufacturing costs.